6 completed, 2 recruiting, 2 terminated, 2 withdrawn. 5 Phase 2, 4 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Withdrawn 2, Completed 1, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow Dense Deposit Disease: new trials by email Literature Review of Dense Deposit Disease trials Research Report on Dense Deposit Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Aliskiren, Enalapril - C3 Glomerulopathy, Membranoproliferative Glomerulonephritis | Phase 2 | Recruiting | Region Skane | 30 | 2020-10-01 | 2025-06-22 |
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 7 | 2018-12-06 | 2021-11-26 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Danicopan - C3 Glomerulonephritis, Dense Deposit Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 6 | 2017-08-09 | 2021-11-04 |
| TP10 Use in Patients With C3 Glomerulopathy (C3G) TP10 - Dense Deposit Disease | Phase 1 | Withdrawn | University of Iowa | 2014-11-01 | 2016-10-27 | |
| Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease CDX-1135 - Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II | Phase 1 | Terminated | Celldex Therapeutics | 1 | 2013-01-01 | 2014-03-07 |
| Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Eculizumab - Dense Deposit Disease, Membranoproliferative Glomerulonephritis | Phase 1 | Completed | Columbia University | 6 | 2010-07-01 | 2019-02-19 |
| National Registry of Rare Kidney Diseases Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis | Recruiting | UK Kidney Association | 35000 | 2009-11-06 | 2023-10-04 | |
| Sulodexide Treatment in Patients With Dense Deposit Disease Sulodexide - Dense Deposit Disease | Phase 1 | Withdrawn | University of Iowa | 2007-12-01 | 2015-06-11 | |
| C3G/Primary IC-MPGN EAP Pegcetacoplan - C3G, IC-MPGN | Approved for marketing | Apellis Pharmaceuticals, Inc. | 2025-11-06 |
Glomerulonephritis, Membranoproliferative (14) · Glomerulonephritis, IGA (2) · Glomerulonephritis, Membranous (2) · Adenine phosphoribosyltransferase deficiency (1) · Atypical Hemolytic Uremic Syndrome (1) · Bartter Syndrome (1) · Calciphylaxis (1) · Cystinosis (1) · Cystinuria (1) · Dent Disease (1) · Denys-Drash Syndrome (1) · Diabetes Insipidus, Nephrogenic (1) · Fabry Disease (1) · Fibromuscular Dysplasia (1) · Gitelman Syndrome (1)
Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Glomerulonephritis (14) · Immune System Diseases (14) · Kidney Diseases (14) · Male Urogenital Diseases (14) · Nephritis (14) · Urogenital Diseases (14) · Urologic Diseases (14) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Skin and Connective Tissue Diseases (2) · Abnormalities, Multiple (1) · Adrenal Gland Diseases (1) · Adrenocortical Hyperfunction (1)
danicopan (3) · pegcetacoplan (3) · Enalapril (1) · aliskiren (1) · eculizumab (1) · glucuronyl glucosamine glycan sulfate (1) · rhoA GTP-Binding Protein (1)
Apellis Pharmaceuticals, Inc. (4) · Alexion Pharmaceuticals, Inc. (3) · University of Iowa (2) · Celldex Therapeutics (1) · Columbia University (1) · Mario Negri Institute for Pharmacological Research (1) · Region Skane (1) · UK Kidney Association (1)
United States (9) · Australia (4) · Belgium (4) · Italy (4) · Netherlands (4) · United Kingdom (4) · Argentina (2) · Brazil (2) · Czechia (2) · France (2) · Israel (2) · Japan (2) · South Korea (2) · Spain (2) · Switzerland (2)
Richard JH Smith, MD (2) · Carla Nester, MD, MSA (1) · Diana Karpman (1) · Gerald B Appel, MD (1) · Richard Smith, MD (1)
PMID 36423588, PMID 42133432, PMID 22403278, PMID 37036696, PMID 37926085, PMID 41337715
2017 (2), 2016 (1), 2019 (1), 2023 (1)